46 Woodstock Road,
Oxford, OX2 6HT
The team focus on breakthrough therapies and platforms, deep science transforming human health, across all therapy areas and modalities.

Tackling the world’s most urgent and complex diseases – from cancer and autoimmune conditions to neurodegeneration and vision loss.

Synthetic biology, antibody engineering, and other platform technologies unlocking new therapies and accelerating discovery.

Tools for stratifying patients, identifying biomarkers, and targeting treatment – reshaping how we understand and treat disease.
From reprogramming immune cells to restoring sight, our companies are redefining what’s possible in human health.

Oxford researchers & innovators
We partner with researchers and innovators across Oxford, Harwell and Culham to explore commercial potential, co-create ventures and build companies.

Investors
We’ve raised over £850m from global investors keen to access Oxford’s diverse, world-leading science. Our shareholders don’t just back OSE – many also co-invest alongside us.

Co-investors
We partner with specialist global investors to fund and scale our companies – from pre-seed to growth. Together, OSE and our co-investors have invested more than £3bn.